Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence | Lupus Science & Medicine

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Archive

Authors

About

Podcasts
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

PDF +
Supplementary
Material

XML

Epidemiology and outcomes

Original research

Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Osmani Z, Schrama TJ, Zacouris-Verweij W, et al

Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence

Lupus Science & Medicine 2021;8:e000478. doi: 10.1136/lupus-2021-000478